ARTL
Artelo BiosciencesCNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-07-21
Current thesis
Positive clinical readout or strategic licensing within ~12 months reduces development risk and limits dilution, enabling a meaningful re-rating toward low-single-digit per-share levels.
Posture
Mixed
Lead driver
Sentiment
What changed
Sentiment remains the lead driver in the composite, 7D delta 0.0.
What can break
Clinical trial failure or disappointing readout
Momentum
1
Value
58
Sentiment
87
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $1.42 · Bull $3.00 · Bear $0.80
Data freshness
Prices
As of 2026-07-21
Fundamentals
As of 2026-07-21 • Vendor: Data Vendor v1
Scores
As of 2026-07-21 • Model: HYBRID_IC_RP
AI Memo
As of 2026-03-03 • Model: RankAlpha Sentiment AI
Investment thesisAs of 2026-07-21
Investment thesis
As of 2026-07-21
Supporting evidence
What
Grade C · Mixed
Confidence Medium · Net Neutral
Target $5.00
Why
Momentum1 · Δ7d -1.0
Value58 · Δ7d +0.1
Sentiment87 · Δ7d 0.0
So what
Balanced signals (Net Neutral). Wait for confirmation before sizing up.
Lead driver: Sentiment · See AI snapshot
Momentum
1
26% active weight
Current posture
7d trendFlat
Δ7d
-1.0
Δ21d
-
Value
58
39% active weight
Current posture
7d trendFlat
Δ7d
+0.1
Δ21d
-0.2
Sentiment
87
34% active weight
Current posture
7d trendFlat
Δ7d
0.0
Δ21d
-
Why this grade
Composite grade C. Momentum 1.1 / Value 57.8 / Sentiment 86.7
Fundamentals (TTM)As of 2026-07-21
Fundamentals (TTM)
As of 2026-07-21
Market Cap
$3.9M
Beta
1.11
Shares Out
3.49M
P/E (TTM) · Derived
-0.0
P/S (TTM)
-
P/FCF (TTM) · Derived
-0.05
Rev YoY
-
EPS YoY
-69.2%
Gross Margin
-
Op Margin
-
Net Debt
$78K
Current Ratio
1.79
As of 2026-07-21 • Updated nightlySource: Internal modelMethodology